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Dear Editor,
Glucocorticoids are widely used to treat acute respiratory 
distress syndrome (ARDS) despite their use being highly 
controversial based on randomized controlled trials and 
meta-analyses [1]. As type I interferons (IFNs) are our 
first line of defense against severe viral respiratory infec-
tions, we explored whether glucocorticoids interfere with 
IFN signaling and whether their use associates with out-
come of IFN beta treatment of ARDS.
Methods are described in the eSupplement. We per-
formed a propensity-matched post hoc analysis using 
data from the recent randomized INTEREST trial 
comparing IFN beta-1a to placebo in ARDS patients 
[2]. Seventy-eight out of 144 patients (54%) included 
in the IFN beta-1a treatment arm of the INTER-
EST trial received glucocorticoids during the 28-day 
study period, 56% (44/78) at randomization (D0), 27% 
(21/78) during the treatment (D1–6) and 17% (13/78) 
after the treatment (D7 onward). Day-28 mortality for 
patients receiving glucocorticoids with IFN beta-1a 
was 39.7% compared to 10.6% for patients receiving 
IFN beta-1a alone. The Kaplan–Meier curves of the 
IFN beta-1a treatment arm adjusted by ARDS severity 
and divided according to the overlapping (D0–D6) use 
of glucocorticoids with IFN beta-1a treatment demon-
strate significantly increased mortality by glucocorti-
coid use (p = 0.0002, see supplement).
In the post hoc propensity-matched analysis of the IFN 
beta-1a arm (n = 144), baseline systemic glucocorticoid 
treatment was independently associated with D28 mor-
tality (OR 5.4, 95% CI 2.1–13.9, p < 0.001) according to 
logistic regression. When the propensity-matched analy-
sis was performed using an exact matching (a precision 
of 0.01 propensity units), there were 49 pairs of patients 
who received or did not receive glucocorticoids (n = 98). 
Among these patients, OR for increased mortality was 
4.6 (95% CI 1.6–13.5) for those who had baseline sys-
temic glucocorticoid treatment and 3.5 (95% CI 1–12) 
for those who initiated glucocorticoid treatment while 
receiving IFN beta-1a (Fig. 1a).
Based on the results of these analyses, we utilized 
human lung tissue and pulmonary endothelial cell cul-
tures to investigate the effect of hydrocortisone on IFN 
nuclear signaling and the protein transcription of CD73, 
a molecule responsible for vascular integrity and leuko-
cyte infiltration to sites of inflammation [3].
When IFN beta-1a was applied to the lung organ 
cultures, CD73 expression was upregulated. However, 
in the presence of hydrocortisone, CD73 upregulation 
was inhibited (Fig. 1b, c). IFN beta-1a signaling via its 
receptor leads to the formation of a heterotrimeric 
transcription complex ISGF3 containing STAT1-STAT2 
and IRF9, which then enters the nucleus and binds to 
the IFN beta responsive elements of several genes or 
assembly on DNA [4]. In pulmonary endothelial cell 
cultures, IFN beta-1a induced the translocation of IRF9 
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into the nucleus, which was reduced by hydrocorti-
sone treatment (Fig. 1d, e). In addition, hydrocortisone 
treatment decreased IRF9 and STAT1 mRNA synthesis 
when measured by qPCR (Fig. 1f ), which was also seen 
at the protein level in Fig. 1d.
We conclude that glucocorticoids inhibit type I IFN 
beta signaling and the upregulation of CD73 in human 
lung. This provides the mechanistic basis for the harm-
ful association of glucocorticoids in IFN beta-treated 
patients in the INTEREST trial. This study takes the 
earlier preclinical evidence that steroids block endog-
enous IFN signaling [5] to the critical care setting. Our 
findings give mechanistic support to the ICM recom-
mendation not to use glucocorticoids at the early stages 
of severe COVID-19 or viral-induced ARDS in general 
and highly recommends not to use systemic glucocor-
ticoids together with type I interferons because of the 
harmful effects of this combination.
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Fig. 1 Glucocorticoid use associates with mortality and blunts IFN beta-induced CD73 upregulation in lung vasculature and IFN beta-1a depend-
ent signaling pathways in pulmonary endothelial cells. a (i) Independent factors associated with Day28 mortality in all IFN beta-1a-treated patients 
(n = 144) by logistic regression adjusted for propensity score and ARDS severity (odds ratios, OR with 95% confidence intervals, CI). (ii) Association of 
glucocorticoid treatment with D28 mortality in only propensity-matched IFN beta-1a-treated patients (n = 98) by logistic regression (OR with 95% 
CI) b Immunohistochemical staining of CD73 (brown) in lung tissue incubated in the presence of IFN beta with or without hydrocortisone (HC) for 
1 and 4 days (D). D0 indicates baseline expression of CD73 in fresh lung tissue. c Quantification of CD73 positive vessels/mm2. The samples were 
incubated in the presence of two different IFN beta-1a formulations (FP-1201, circles n = 10 (day 1) and n = 11 (day 4); DS, triangles n = 8). Each 
data point marks an individual. The dotted line represents the placebo-induced level of CD73 expression. Statistical significance was analyzed using 
the Mann–Whitney test. d Immunofluorescence staining of IRF9 in primary human pulmonary endothelial cells after IFN beta treatment with or 
without HC showing marked inhibition of nuclear translocation of IRF9 by HC, the representative results of three independent experiments with the 
similar results. e Immunoblotting of the cytosolic and nuclear fractions of pulmonary endothelial cells after IFN beta-1a ± HC demonstrating both 
decreased IRF9 signal and its nuclear translocation. Specific IRF9 band is indicated by an arrow, a representative blot of five independent analyses 
with the comparable results. GAPDH and H3 (histone) are loading controls for the cytoplasmic and nuclear fractions, respectively. f qPCR results of 
two independent experiments demonstrating the decrease in IFN beta-1a-triggered mRNA synthesis of IRF9 and STAT1 by HC. Scale bars 100 μm
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